QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:UROV

Urovant Sciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$16.24
0.00 (0.00%)
(As of 03/29/2021)
Add
Compare
Today's Range
$16.24
$16.24
50-Day Range
$16.19
$16.24
52-Week Range
$7.15
$16.26
Volume
N/A
Average Volume
114,469 shs
Market Capitalization
$531.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.36

Receive UROV News and Ratings via Email

Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter.


Urovant Sciences logo

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Headlines

Urovant Sciences Ltd. Common Shares (UROV)
July 25, 2021 |  nasdaq.com
Bicycle Therapeutics Ltd. ADR
March 21, 2021 |  wsj.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:UROV
Fax
N/A
Employees
70
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($1.90) per share

Profitability

Net Income
$-146.74 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$531.75 million
Optionable
Not Optionable

Company Calendar

Last Earnings
2/11/2021
Today
12/07/2021

MarketRank

Overall MarketRank

0.90 out of 5 stars

Medical Sector

1290th out of 1,394 stocks

Pharmaceutical Preparations Industry

630th out of 673 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Urovant Sciences (NASDAQ:UROV) Frequently Asked Questions

How were Urovant Sciences' earnings last quarter?

Urovant Sciences Ltd. (NASDAQ:UROV) released its quarterly earnings data on Thursday, February, 11th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.59) by $0.13.
View Urovant Sciences' earnings history
.

Who are Urovant Sciences' key executives?

Urovant Sciences' management team includes the following people:
  • Mr. James A. Robinson Jr., Pres, CEO & Director (Age 50, Pay $1.07M)
  • Mr. Ajay Bansal, CFO & Sr. VP of Bus. Devel. (Age 59, Pay $558.34k)
  • Dr. Cornelia Haag-Molkenteller M.D., Ph.D., Chief Medical Officer of USI (Age 62, Pay $629.79k)
  • Ms. Christine G. Ocampo, Chief Accounting Officer & Sr. VP (Age 49)
  • Ryan Kubota, Exec. Director of Investor Relations
  • Mr. Bryan E. Smith, Gen. Counsel (Age 42)
  • Dr. David Hovland, Sr. VP of Global Regulatory Affairs
  • Mr. Kenton Stewart, Sr. VP of Market Access

What other stocks do shareholders of Urovant Sciences own?

When did Urovant Sciences IPO?

(UROV) raised $150 million in an IPO on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO.

What is Urovant Sciences' stock symbol?

Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV."

What is Urovant Sciences' stock price today?

One share of UROV stock can currently be purchased for approximately $16.24.

How much money does Urovant Sciences make?

Urovant Sciences has a market capitalization of $531.75 million. The company earns $-146.74 million in net income (profit) each year or ($4.71) on an earnings per share basis.

How many employees does Urovant Sciences have?

Urovant Sciences employs 70 workers across the globe.

What is Urovant Sciences' official website?

The official website for Urovant Sciences is www.urovant.com.

Where are Urovant Sciences' headquarters?

How can I contact Urovant Sciences?

Urovant Sciences' mailing address is 11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-0-20-7400-3347 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.